Walleye Capital LLC Makes New Investment in Alumis Inc. $ALMS

Walleye Capital LLC bought a new stake in shares of Alumis Inc. (NASDAQ:ALMS) during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund bought 31,778 shares of the company’s stock, valued at approximately $700,000.

A number of other hedge funds also recently modified their holdings of ALMS. Ieq Capital LLC boosted its position in shares of Alumis by 4.1% in the fourth quarter. Ieq Capital LLC now owns 17,421 shares of the company’s stock worth $170,000 after buying an additional 690 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Alumis by 26.1% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,724 shares of the company’s stock valued at $46,000 after buying an additional 979 shares in the last quarter. Strs Ohio raised its position in Alumis by 300.0% during the first quarter. Strs Ohio now owns 2,000 shares of the company’s stock valued at $44,000 after buying an additional 1,500 shares during the period. ProShare Advisors LLC raised its position in Alumis by 12.4% during the fourth quarter. ProShare Advisors LLC now owns 14,627 shares of the company’s stock valued at $143,000 after buying an additional 1,618 shares during the period. Finally, KBC Group NV acquired a new position in Alumis during the first quarter valued at $42,000.

Analyst Upgrades and Downgrades

ALMS has been the subject of a number of research reports. Morgan Stanley restated an “overweight” rating and set a $39.00 price objective on shares of Alumis in a research report on Friday, May 15th. Guggenheim upped their target price on Alumis from $32.00 to $34.00 and gave the company a “buy” rating in a report on Friday, May 15th. Chardan Capital increased their price target on shares of Alumis from $38.00 to $40.00 and gave the stock a “buy” rating in a research report on Tuesday, May 19th. Oppenheimer raised their price target on shares of Alumis from $50.00 to $55.00 and gave the stock an “outperform” rating in a report on Monday, March 30th. Finally, Citigroup reaffirmed a “buy” rating on shares of Alumis in a research report on Tuesday, May 19th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $40.30.

Alumis Trading Down 1.1%

Shares of NASDAQ:ALMS opened at $28.00 on Friday. Alumis Inc. has a 1 year low of $3.75 and a 1 year high of $31.35. The business has a fifty day simple moving average of $24.50 and a 200 day simple moving average of $24.72. The firm has a market cap of $3.57 billion, a price-to-earnings ratio of -14.14 and a beta of -0.73.

Alumis (NASDAQ:ALMS) last issued its earnings results on Thursday, May 14th. The company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.01). Alumis had a negative net margin of 2,825.70% and a negative return on equity of 88.79%. The firm had revenue of $1.74 million during the quarter, compared to analysts’ expectations of $2.10 million. On average, sell-side analysts forecast that Alumis Inc. will post -2.87 EPS for the current year.

Insider Activity

In other news, insider Sanam Pangali sold 5,000 shares of Alumis stock in a transaction dated Monday, July 6th. The stock was sold at an average price of $28.00, for a total transaction of $140,000.00. Following the completion of the sale, the insider directly owned 11,111 shares in the company, valued at $311,108. The trade was a 31.03% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 33.70% of the stock is currently owned by corporate insiders.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.